SCHEMBL17114378

SCHEMBL17114378

C#C[C@]1(CO)OC(c2cnn3c(N)ncnc23)CC1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17106717 1.00 — —
SCHEMBL17106700 0.87 — —
SCHEMBL17114386 0.87 — —
SCHEMBL17106687 0.83 — —
SCHEMBL17131366 0.83 — —
SCHEMBL17114363 0.82 SLC28A1 (0.30) —
SCHEMBL17106834 0.82 SLC28A1 (0.30) —
SCHEMBL17106774 0.79 — —
SCHEMBL17106723 0.76 POLRMT (0.33) —
SCHEMBL17106850 0.75 HSPA5 (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122752-A1 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-02-01 — — EP disclosed
WO-2015148746-A1 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-01 — — WO disclosed
Send feedback